Health Library
April 21, 2026
Question on this topic? Get an instant answer from August.
Most people on a GLP-1 drug start seeing scale move within first month. By month six, average person on semaglutide 2.4 mg has lost around 10% of their starting weight. By month 15 to 18, that number climbs to about 15% to 17%. After that, weight tends to level off and stay there as long as you keep taking medication.
Those are averages. Your own numbers will depend on drug, dose, how your body responds, and whether you're making dietary changes alongside medication. But pattern is consistent across thousands of patients in clinical trials and real world practice. This article walks through what that timeline actually looks like, stage by stage.

The first thing you'll notice is that your appetite drops. Most people feel this within first week or two. You sit down to eat and you're done sooner than expected. The urge to snack between meals fades. Some people describe it as constant background hum of food thoughts going quiet.
On scale, first month is usually modest. You might lose 2 to 4 pounds. That's because you're on lowest starter dose during this phase. For Wegovy, that's 0.25 mg. For Zepbound, it's 2.5 mg. These starter doses are designed to let your gut adjust before ramping up.
Gastrointestinal side effects are most common during this early period. Nausea is one people talk about most. It tends to show up in first few days after each injection, especially first one. For most people, it's mild and fades after a week or two. Some people also get constipation, diarrhea, or sulfur-tasting burps, which are unpleasant but temporary.
Eating smaller portions and avoiding greasy or heavy foods during this period helps. So does staying hydrated.
This is when things start to move. You're titrating up to higher doses every four weeks during this stretch. Each dose increase tends to bring a new burst of appetite suppression, followed by a brief wave of nausea that usually settles within a few days.
By month three, most people on semaglutide have lost somewhere around 5% to 7% of their starting body weight. By month six, that number is closer to 10% to 12%. For tirzepatide users, numbers tend to run a few percentage points higher at each checkpoint.
You'll start noticing physical changes beyond scale. Clothes fit differently. Your face may look thinner. Your waist measurement drops. If you had joint pain from carrying extra weight, it might start easing up. Blood pressure often starts to improve during this window too.
The nausea tends to level off by month three or four for most people. Your body adapts to medication. Some people barely notice side effects after initial titration phase.
This is typically period of fastest weight loss. You've reached or are close to your maintenance dose. Your appetite is consistently reduced. Your eating habits have likely shifted to smaller meals, less snacking, and fewer cravings.
In STEP 1 trial, semaglutide users lost about 12% of their starting weight by month nine. By month 12, average was around 14%. The curve starts to flatten here, meaning rate of loss slows down even though you're still losing.
People with type 2 diabetes tend to see slightly less weight loss during this window compared to non-diabetic patients. The average in STEP 2 (diabetes trial) was about 9.6% at 68 weeks. Still meaningful, but metabolic effects of diabetes make fat loss harder.
This is also period where you might notice your hair thinning. Telogen effluvium, which is temporary hair shedding triggered by rapid weight change, can show up around months four through eight. It's a stress response from your body, not a drug side effect. It almost always reverses on its own once your weight stabilizes.
Weight loss peaks somewhere in this range for most people. In STEP 1 trial, lowest average weight was recorded around week 60, which is roughly month 14. After that, curve flattened. Patients on semaglutide 2.4 mg ended 68-week trial with an average loss of 17.3%.
This is not a plateau in way people usually fear. The drug is still working. Your appetite is still suppressed. You're still eating less. But your body has found a new balance point where calories you consume roughly match what you burn at your new, lower weight.
At this stage, people who started with a BMI above 35 or 40 often report that their daily life feels different. Walking is easier. Energy levels are steadier. Sleep is better. Lab markers like blood sugar, cholesterol, and blood pressure have often improved by now.
The STEP 5 trial followed patients on semaglutide for a full two years. At week 104, average weight loss was 15.2%, nearly identical to what they'd achieved at month 12 to 14. That means weight stayed off. It didn't creep back. As long as people kept taking drug, results held.
This is an underappreciated point. The "after" for people who continue treatment is stable. You reach a new weight, and you stay there.
The cardiometabolic improvements also held steady. Blood sugar, blood pressure, waist circumference, and cholesterol levels remained improved at two-year mark.
This is part that matters and doesn't get talked about enough. The STEP 1 extension study followed 327 participants after they stopped taking semaglutide at week 68. One year later, they had regained about two-thirds of weight they'd lost. The average net loss from baseline to week 120 was only 5.6%, down from 17.3% at end of treatment.
Their cardiometabolic improvements also reversed. Blood pressure, waist circumference, and blood sugar drifted back toward their pre-treatment levels.
This isn't a failure of drug or a failure of willpower. Obesity is a chronic condition with biological drivers. When you remove medication, hormonal signals that regulate appetite and fat storage return to where they were before. Your brain starts sending hunger signals at pre-treatment levels. Your metabolic rate adjusts downward.
This is why most doctors now recommend staying on GLP-1 therapy long term, similar to how you'd stay on blood pressure medication if you had hypertension. Some providers explore lower maintenance doses after weight loss to reduce cost and side effects while preserving results. That approach is still being studied, but early data is encouraging.
If you're starting a GLP-1 drug for weight loss, here is a rough timeline based on available data.
Month 1: appetite drops, 1 to 2% body weight lost, possible nausea
Month 3: 5 to 7% lost, clothes fitting looser, side effects easing
Month 6: 10 to 12% lost, visible physical changes, blood pressure improving
Month 12: 14 to 17% lost, near peak weight loss
Month 18 and beyond: weight stabilizes at new level if medication continues
These numbers are averages. Some people lose more. Some lose less. People with type 2 diabetes tend to fall toward lower end. People without diabetes and on higher doses tend to fall toward higher end. Women tend to lose slightly more than men in percentage terms.
The most honest thing anyone can tell you is that GLP-1 drugs produce real, measurable, clinically meaningful weight loss. They don't produce miracles, and they don't work forever on their own. They work while you take them, and results last as long as you stay on treatment.
Get clear medical guidance
on symptoms, medications, and lab reports.
Download August today. No appointments. Just answers you can trust.